tirzepatide parkinson and Multiple Sclerosis: Safety and Clinical Considerations GLP-1 does not slow Parkinson's

These include: In clinical trials, patients using semaglutide for weight loss achieved an average reduction of 10-15% of their body weight over a year

Most people tolerate GLP-1 treatment well

The shorter working life of a 50mg vial is part of its advantage over the 100mg presentation, so avoid extending it unnecessarily

Understanding how tirzepatide interacts with thyroid conditions ensures safe, effective treatment tailored to your individual physiology

Seek urgent care if you experience: Confusion Fainting Very low urine output Severe dizziness A fast, irregular heartbeat If symptoms do not improve after rehydration Quick Practical Tips You Can Use Today Carry a refillable bottle and aim to finish it several times a day

An Ozempic plateau typically means your rate of weight loss has slowed, not that the medication has stopped working